Segment Disclosures (Tables)

12 Months Ended

Dec. 31, 2024

Segment Reporting [Abstract]

Summary Of Significant Expense Related To The Life Science Segment

The table below summarizes segment net loss, including significant expenses for the years ended December 31, 2024 and 2023 (in thousands):

	Year Ended December 31,
	2024			2023
Royalty revenues and sale of royalty rights	$	16,146		$	—
Costs and operating expenses
Cost of revenues		475			—
Research and development
Clinical product candidates		24,456			10,638
Clinical product manufacturing		11,200			3,333
Personnel-related expenses excluding stock-based compensation		14,293			21,885
Stock-based compensation		3,002			4,409
Depreciation and amortization		1,922			1,634
Other (i)		3,874			7,687
Total research and development expenses		58,747			49,586
General and administrative
Personnel-related expenses excluding stock-based compensation		5,837			8,553
Stock-based compensation		9,943			12,537
Professional and consultant fees		4,491			6,347
Other (ii)		5,149			5,173
Total general and administrative expenses		25,420			32,610
Impairment of in-process research and development intangible asset		20,964			—
Total costs and operating expenses		105,606			82,196
Other segment income (iii)		9,965			8,406
Income tax benefit		(2,164	)		—
Segment net loss	$	(77,331	)	$	(73,790	)
Reconciliation of profit or loss
Adjustments and reconciling items		—			—
Consolidated net loss	$	(77,331	)	$	(73,790	)

(i)	Other research and development segment items include facilities expenses, lab services, professional services, technology costs, depreciation and amortization of intangible assets.
(ii)	Other general and administrative segment items include facilities expenses, technology costs, insurance and depreciation.
(iii)	Other segment income for the years ended December 31, 2024 and 2023 consisted of $7.0 million and $6.6 million of interest and investment income and $2.9 million and $1.8 million of sublease income, respectively.